Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent

Inflammatory Bowel Diseases

Volumn 14, Issue 6, 2008, Pages 780-793

  Billerey Larmonier, Claire ^a   Uno, Jennifer K ^b   Larmonier, Nicolas ^a   Midura, Anna J ^a   Timmermann, Barbara ^c,d   Ghishan, Fayez K ^a   Kiela, Pawel R ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

Animal models of IBD; BALB c; Microarray; SJL J; Trinitrobenzene sulfonic acid (TNBS)

Indexed keywords

CONCANAVALIN A; CURCUMIN; INTERLEUKIN 4; INTERLEUKIN 5; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CHEMICALLY INDUCED DISORDER; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DIETARY INTAKE; DISEASE ACTIVITY; GENE EXPRESSION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STRAIN DIFFERENCE; SURVIVAL; SWISS JAMES LAMBERT MOUSE; WEIGHT REDUCTION;

ANIMALS; COLITIS; CONCANAVALIN A; CURCUMIN; DIET; DISEASE MODELS, ANIMAL; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICROARRAY ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECIES SPECIFICITY; TRINITROBENZENESULFONIC ACID;

EID: 46049110157     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20348     Document Type: Article

References (51)

1. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
2. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev. 2004;3:394-400.
3. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet. 2001;10:445-456.
4. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
5. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
6. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112:1169-1178.
7. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997;150:823-832.
8. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490-1497.
9. Plevy SE, Gemberling JH, Hsu S, et al. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol Cell Biol. 1997;17:4572-4588.
10. Becker C, Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest. 2003;112:693-706.
11. Hilliard BA, Mason N, Xu L, et al, Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest. 2002;110: 843-850.
12. Zhang Z, Andoh A, Yasui H, et al. Interleukin-1beta and tumor necrosis factor-alpha upregulate interleukin-23 subunit p19 gene expression in human colonic subepithelial myofibroblasts. Int J Mol Med. 2005;15: 79-83.
13. Das J, Chen CH, Yang L, et al. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nature Immunol. 2001;2:45-50.
14. Pahl A, Zhang M, Kuss H, et al. Regulation of IL-13 synthesis in human lymphocytes: implications for asthma therapy. Br J Pharmacol. 2002; 135:1915-1926.
15. Fichtner-Feigl S, Fuss IJ, Preiss JC, et al. Treatment of murine Th1-and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest. 2005;115:3057-3071.
16. Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999;163:3474-3483.
17. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol. 2007;27:19-35.
18. Yadav VS, Mishra KP, Singh DP, et al. Immunomodulatory effects of curcumin. Immunopharmacol Immunotoxicol. 2005;27:485-497.
19. Kim GY, Kim KH, Lee SH, et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol. 2005;174:8116-8124.
20. Bhaumik S, Jyothi MD, Khar A. Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett. 2000;483:78-82.
21. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44:97-111.
22. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41:1955-1968.
23. Jian YT, Mai GF, Wang JD, et al. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol. 2005;11:1747-1752.
24. Salh B, Assi K, Templeman V, et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol. 2003;285: G235-G243.
25. Sugimoto K, Hanai H, Tozawa K, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology. 2002;123:1912-1922.
26. Ukil A, Maity S, Karmakar S, et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003;139:209-218.
27. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502-1506.
28. Dohi T, Fujihashi K, Rennert PD, et al. Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J Exp Med. 1999;189:1169-1180.
29. Bouma G, Kaushiva A, Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology. 2002;123:554-565.
30. Fuss IJ, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology. 1999;117:1078-1088.
31. Cong Y, Weaver CT, Lazenby A, et al. Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12. J Immunol. 2000;165:2173-2182.
32. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med. 1996;183:693-698.
33. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997;27:1743-1750
34. Singh AK, Yang JQ, Parekh VV, et al. The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol. 2005;35:1143-1154.
35. Beutner U, Launois P, Ohteki T, et al. Natural killer-like T cells develop in SJL mice despite genetically distinct defects in NK1.1 expression and in inducible interleukin-4 production. Eur J Immunol. 1997;27:928-934.
36. Kiela PR, Midura AJ, Kuscuoglu N, et al. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G798-G808.
37. Dennis G, Jr., Sherman BT, Hosack DA, et al. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 2003; 4:P3.
38. Ho Sui SJ, Fulton DL, Arenillas DJ, et al. oPOSSUM: integrated tools for analysis of regulatory motif over-representation. Nucleic Acids Res. 2007;35:W245-W252.
39. Aggarwal BB, Surh Y-J, Shishodia S, eds. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. 2007/06/16 ed. New York: Springer; 2007.
40. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50:2191-2193.
41. Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. In: Coico R, ed. Current Protocols in Immunology. John Wiley & Sons, Inc.; 2001: 15.19.11-15.19.14.
42. Kang BY, Song YJ, Kim KM, et al. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin-12 production in macrophages. Br J Pharmacol. 1999;128:380-384.
43. Zhang M, Deng CS, Zheng JJ, et al. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacologica Sinica. 2006;27:1071-1077.
44. Nakamura K, Honda K, Mizutani T, et al. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol. 2006;12:4628-4635.
45. Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis. 2005;37:811-818.
46. Youn HS, Saitoh SI, Miyake K, et al. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol. 2006;72:62-69.
47. Gradisar H, Keber MM, Pristovsek P, et al. MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol. 2007.
48. Marciniak SJ, Yun CY, Oyadomari S, et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004;18:3066-3077.
49. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 1992;6:439-453.
50. Shen J, Chen X, Hendershot L, et al. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell. 2002;3:99-111.
51. Nguyen DD, Maillard MH, Cotta-de-Almeida V, et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology. 2007;133:1188-1197.